ZIOPHARM oncology names Hagop Youssoufian CMO
This article was originally published in Scrip
ZIOPHARM Oncology, a drug development company employing small molecule and synthetic biology approaches to cancer therapy, has appointed Dr Hagop Youssoufian executive vice-president and chief medical officer, reporting to Dr Jonathan Lewis, ZIOPHARM's CEO. Dr Youssoufian has nearly 30 years' experience with companies such as Bristol-Myers Squibb, Sanofi-Aventis and, most recently, ImClone Systems.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.